Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
ME
Jyong Biotech Ltd. Ordinary Shares
MENS
Volume
40.47K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
ME
MENS
ME
Jyong Biotech Ltd. Ordinary Shares
MENS
News
·
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
Mkt Cap
$147.0M
Volume
40.47K
Next Earnings
N/A
Chart
Financials
Earnings
News
About
Insider
Filings
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
Jyong Biotech reaffirms its strategic focus on global licensing partnerships to address the growing BPH market. The company highlights that the global BPH patient population reached 112.5 million in 2021 and is projected to grow to 150-156 million by 2035, with the market size expected to grow from $13 billion in 2025 to $22-22.6 billion by 2035. Jyong Biotech's lead candidate Botreso® (API-1) has completed four Phase III clinical trials and aims to address unmet medical needs caused by severe side effects of existing treatments.
GlobeNewswire Inc. · Jul 23, 2026
Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400%
The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.
Benzinga · Oct 7, 2025
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
The Motley Fool · Sep 3, 2025
Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)
Jyong Biotech presented Phase III clinical trial results for BOTRESO, a drug for benign prostatic hyperplasia, and Phase II results for MCS-8, a potential prostate cancer prevention drug, at the 22nd Urological Association of Asia Congress.
GlobeNewswire Inc. · Aug 22, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
ME
MENS
Jyong Biotech Ltd. Ordinary Shares
Buy
Sell
Market
Limit
Soon
MENS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any MENS yet.
Related Tickers
Earnings